AASLD Highlights

$ Hepatology Update: The Year in Review

Moderators: Paul Martin, MD, FAASLD, and Michael H. Nathanson, MD, PhD, FAASLD
Saturday, May 21, 2016, 2–5 p.m.

This program aims to improve patient care by increasing clinicians’ awareness of recent research that strengthens current clinical care protocols. Investigators will discuss new discoveries that advance the field of hepatology. This program represents a unique opportunity for expert hepatologists to summarize clinical and basic research publications on topics that are highly relevant to the practice of hepatology and liver-based research.

Registration Fees 

Registration Type

On Or Before
April 6
After April 6
AASLD Member $105 $155
Nonmember $205 $255


Preliminary Schedule


2 p.m. Welcome and Introduction
2:05 p.m. End-Stage Liver Disease and Its Complications
2:35 p.m. Liver Cancer
3:05 p.m. NAFLD
3:35 p.m. Break
3:55 p.m. Advances in Management of HCV
4:25 p.m. Implications of Change in Organ Allocation
4:55 p.m. Wrap-Up

Plenary Sessions

Sunday, May 22, 2016, and Monday, May 23, 2016, 8–9:30 a.m.

The best abstracts in basic and clinical hepatology will be presented at these highly focused sessions.

Clinical Symposia

Optimizing Hepatitis B Treatment

Sunday May 22, 2016, 8–9:30 a.m.

The purpose of this program is to review the updated AASLD guidelines on hepatitis B and to discuss novel antiviral and immunotherapy strategies. This program will be comprised of three talks that combine evidence-based reviews and case discussions to facilitate implementation of guidelines recommendations in clinical practice. It will also discuss limitations of existing therapies, and challenges and promises in developing novel therapies aimed at HBV cure.

Therapy for NASH: Current Status and Emerging Therapies

Sunday May 22, 2016, 2–3:30 p.m.

This program provides a practical approach to managing patients with NAFLD. It will cover how to identify patients at highest risk for the development of advanced disease based on important clinical predictors as well as incorporate the most recent data on biomarkers. The role of liver biopsy and how to interpret findings to assess prognosis and guide therapy will be discussed.

Available therapies for NASH and the rationale for a given therapy in various clinical contexts as well as emerging therapies for NASH will be discussed.

Prospects for HCV New Treatments

Sunday May 22, 2016, 2–3:30 p.m.

Hepatitis C therapy is rapidly evolving and current therapy offers high rates of cure for most patients. However, sustained virological response is not universal and treatment regimens may be modified to improve outcomes. This symposium will discuss strategies to optimize outcomes for populations that remain at risk for treatment failure, review key concepts and management of viral resistance, and review the latest advances in HCV therapy.

Cancer and Non-alcoholic Fatty Liver Disease

Monday, May 23, 2016, 4–5:30 p.m.

This symposium will review the epidemiology, pathogenesis and management issues relevant to an emerging clinical problem: hepatocellular cancer in the setting metabolic syndrome and non-alcoholic fatty liver disease.

Hepatocellular Cancer

Tuesday, May 24, 2016, 10–11:30 a.m.

This program will provide attendees with an understanding of the appropriate patients for HCC surveillance and the potential utility of the GALAD score in surveillance. The role of HCC surveillance in patients who have achieved sustained virologic response after HCV treatment will also be discussed. Also addressed in this session will be the new UNOS prioritization for patients with HCV and the appropriate selection of patients beyond the Milan criteria for liver transplant. The session will conclude with a discussion on the role/rationale of PD1/PD-L1 inhibition in HCC, the selection of patients for PD1/PD?L1 inhibitor treatment, and management of potential side effects.

Update on Cholestatic Liver Disease

Tuesday, May 24, 2016, 2–3:30 p.m.

Cholestatic liver diseases, namely primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are rare diseases that remain challenging due to the lack or absence of effective therapies. This program is intended to impart new knowledge about how recent insights into PBC and PSC are leading to novel therapeutic approaches and management options. Moreover, the program will address emerging technologies that can be used to risk-stratify patients, targets for drug development, and approaches to common clinical problems in cholestatic liver diseases. This information will be essential not only for patient management in future years, but to optimize the design of clinical trials in the largest number of patients in order to safely test the efficacy of candidate drugs.

The Intestinal Microbiome and Pediatric Liver Disease
(co-sponsored with NASPGHAN)

Tuesday, May 24, 2016, 4–5:30 p.m.

This activity will introduce to clinical practitioners an emerging area of study and stimulate liver researchers to incorporate new findings about the microbiome into their work. This symposium is expected to eventually lead to changes in clinical practice that will benefit patients with liver disease.

State-of-the-Art Lectures

Hepatitis C: Update 2016

Sunday, May 22, 2016, 10–11 a.m.
Speaker: Norah Terault, MD

Upon completion of this activity participants will be able to:

  • Identify ways the HCV care cascade and the important role of screening, linkage to care and appropriate treatment triage.
  • Increase the number of apply the current AASLD-IDSA treatment guidelines to making decisions regarding the optimal therapy for a given HCV-infected patient.
  • Recognize the limitations of current therapy, especially in regard to emergence of resistance and impact on future treatment options.
  • Maximize SVR rates through improved understanding of antiviral drug selection, management of drug-drug interaction and adherence.

Fibrosis in Chronic Liver Disease: Progress in Assessment and Treatment

Sunday, May 22, 2016, 4–5 p.m.
Speaker: Rohit Loomba, MD

Upon completion of this activity participants will be able to:


  • Apply new insights into fibrosis pathogenesis and assessment.
  • Summarize new approaches to treating fibrosis.

Alcoholic Liver Disease

Monday, May 23, 2016, 10–11 a.m.
Speaker: Gyongyi Szabo, MD, PhD, FAASLD

Upon completion of this activity participants will be able to:

  • Apply state-of-the-art updates to providers in alcoholic liver disease.
  • Review current understanding of the epidemiology, pathogenesis, natural history and treatment in alcoholic liver disease and alcoholic hepatitis.
  • Recognize gaps in the diagnosis, and associate the natural history and treatment options in alcoholic liver disease and alcoholic hepatitis.
  • Provide an update on emerging clinical developments and treatment trials in alcoholic liver disease and alcoholic hepatitis.

Management of Liver Disease and the Affordable Care Act: Population Health, Rationing Care

Tuesday, May 24, 2016, 8–9 a.m.
Speaker: Jayant A. Talwalkar, MD, MPH

Upon completion of this activity participants will be able to:


  • Describe the basic components of the Patient Protection and Affordable Care Act (PPACA).
  • Recognize the current impacts of health insurance coverage and delivery system transformation on populations with chronic liver disease.
  • Discuss future implications of the fully realized PPACA on management and reimbursement for liver disease care.

Other AASLD Programming

Research/Topic Fora, held Sunday, May 22, through Tuesday, May 24, will offer opportunities for presentation of original research and exchange of ideas and data. Topics include:

  • Autoimmune/Cholestatic Liver Disease.
  • Cell and Molecular Biology.
  • Hepatitis B and C.
  • Liver Transplantation.
  • Viral Hepatitis.

AASLD General Learning Objectives

  • Provide a forum for the exchange of new scientific and clinical information relevant to the study of liver disease.
  • Create an arena for the interchange of opinions regarding the care and management of all types of liver disease.
  • Assess new diagnostic or therapeutic techniques related to liver disease. 

$ = An additional fee is required for this session.